Metabolism of antitumor acylfulvene by rat liver cytosol

Biochemical Pharmacology

Volumn 57, Issue 1, 1999, Pages 83-88

  McMorris, Trevor C ^a   Elayadi, Anissa N ^a   Yu, Jian ^a   Kelner, Michael J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acylfulvene; Acylfulvene metabolism; Antitumor agents; Illudin S; Rat liver cytosol

Indexed keywords

ACYLFULVENE; ANTINEOPLASTIC AGENT; ILLUDIN DERIVATIVE; ILLUDIN S; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL REACTION KINETICS; CRYSTAL STRUCTURE; DRUG ISOLATION; DRUG POTENCY; HYDROXYLATION; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

EID: 0032924960     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00273-1     Document Type: Article

References (13)

1. McMorris T.C., Anchel M. Fungal metabolites. The structure of the novel sesquiterpenoids illudin-S and -M. J Am Chem Soc. 87:1965;1594-1600.
2. Ammirati J.F., Traquair J.A., Horgen P.A. Poisonous Mushrooms of the Northern United States and Canada, Section about Gastrointestinal Irritants. 1985;290-292 University of Minnesota Press, Minneapolis.
3. Kelner M.J., McMorris T.C., Beck W.T., Zamora J.M., Taetle R. Preclinical evaluation of illudins as anticancer agents. Cancer Res. 47:1987;3186-3189.
4. McMorris T.C., Kelner M.J., Wang W., Diaz M.A., Estes L.A., Taetle R. Acylfulvenes, a new class of potent antitumor agents. Experientia. 52:1996;75-80.
5. Kelner M.J., McMorris T.C., Estes L., Starr R.J., Rutherford M., Montoya M., Samson K., Taetle R. Efficacy of acylfulvene illudin analogs against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res. 55:1995;4936-4940.
6. Kelner M.J., McMorris T.C., Estes L., Wang W., Samson K., Taetle R. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs. 14:1996;161-167.
7. MacDonald J.R., Muscoplat C.C., Dexter D.L., Mangold G.L., Chen S., Kelner M.J., McMorris T.C., Von Hoff D.D. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res. 57:1997;279-283.
8. McMorris T.C., Kelner M.J., Wang W., Moon S., Taetle R. On the mechanism of toxicity of illudins: The role of glutathione. Chem Res Toxicol. 3:1990;574-579.
9. Tanaka K., Inoue T., Kadota S., Kikuchi T. Metabolism of illudin S, a toxic principle of Lampteromyces japonicus, by rat liver. I. Isolation and identification of cyclopropane ring-cleavage metabolites. Xenobiotica. 20:1990;671-681.
10. Anchel M., McMorris T.C., Singh P. The biogenesis of illudins S and M in Clitocybe illudens. Phytochemistry. 9:1970;2339-2343.
11. Tanaka K., Inoue T., Kadota S., Kikuchi T. Metabolism by rat liver cytosol of illudin S, a toxic substance of Lampteromyces japonicus. II. Characterization of illudin S-metabolizing enzyme. Xenobiotica. 22:1992;33-39.
12. Tanaka K., Inoue T., Kadota S., Kikuchi T. Metabolism of illudin S, a toxic substance of Lampteromyces japonicus. IV. Urinary excretion of an illudin S metabolite in rat. Xenobiotica. 24:1994;1237-1243.
13. Klaassen C.D., Amdur M.O., Doull J., Casarett and Doull's Toxicology. 1986;MacMillan Publishing, New York.